TickerKhojPharmaceuticals · Biotechnology · NSE: RUBICON · data 2026-11-02
Rubicon Research Limited
In plain words
Price: 12.7% below its 52-week high of ₹1,899.
Delivery: 51.6% of traded shares were kept for delivery over the last 10 sessions, against 49.7% over the last 60.
Latest results: a net profit of ₹85 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,936 cr |
| Net profit (last 12 months) | ₹288 cr |
| Sales growth, 3 years (yearly) | 64.7% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 51.3%, pledged 0.0%, institutions 24.7%.
P/E 95.5, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 27.0%, ROCE 32.4%, operating margin 20.6%: how much profit it earns on the money it uses.
Debt/equity 0.24, Profit growth — and sales growth 64.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (27.0%).
- Healthy operating margin (20.6%).
- Expensive on earnings (P/E 95.5).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
RUBICON Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹534.34 crore, up 4% QoQ.
Net profit was ₹84.78 crore, up 10.4% QoQ.
Operating margin was 24.2%.
EPS was ₹5.13, up 10.1% QoQ.
RUBICON के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹534.34 करोड़; पिछली तिमाही की तुलना में 4% की बढ़त।
शुद्ध मुनाफ़ा: ₹84.78 करोड़; पिछली तिमाही की तुलना में 10.4% की बढ़त।
ऑपरेटिंग मार्जिन: 24.2%।
EPS: ₹5.13; पिछली तिमाही की तुलना में 10.1% की बढ़त।
RUBICONના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹534.34 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 4% વધારો.
ચોખ્ખો નફો: ₹84.78 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 10.4% વધારો.
ઓપરેટિંગ માર્જિન: 24.2%.
EPS: ₹5.13; ગયા ક્વાર્ટરની સરખામણીએ 10.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
27/100 · Neutral over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 7/30: Delivery 54.1% over the last 20 sessions vs 44.7% in the 40 before (1.21x); shares delivered per day 0.59x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 3 schemes hold it, about ₹268 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 48/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 14 Aug 26Results Q1 FY27 results: net profit ₹84.8 cr +11.0% next session
- 7 Aug 26Dividend Dividend ₹1.5 (ex-date) +4.1% next session
- 29 May 26Results Q4 FY26 results: net profit ₹76.8 cr +21.0% next session
- 3 Feb 26Results Q3 FY26 results: net profit ₹72.8 cr +12.3% next session
- 13 Nov 25Results Q2 FY26 results: net profit ₹53.9 cr +13.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹534 cr | ₹85 cr | — | 24.2% | 5.13 |
| Mar 2026 | ₹514 cr | ₹77 cr | — | 23.1% | 4.66 |
| Dec 2025 | ₹476 cr | ₹73 cr | — | 22.7% | 4.46 |
| Sept 2025 | ₹412 cr | ₹54 cr | — | 22.9% | 3.49 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 51.25% | 59.76% | 59.86% | 59.99% |
| Foreign institutions (FII) | 9.01% | 7.52% | 7.54% | 7.99% |
| Domestic institutions (DII) | 15.72% | 9.43% | 10.02% | 9.45% |
| Mutual funds | 13.78% | 7.23% | 7.14% | 6.61% |
| Retail investors | 3.34% | 3.16% | 2.51% | 2.71% |
| Number of shareholders | 38,018 | 43,254 | 33,738 | 31,914 |
Common questions
What was Rubicon Research Limited's latest quarterly profit?
Rubicon Research Limited reported a net profit of ₹85 cr for the quarter ended Jun 2026, on revenue of ₹534 cr.
How much do promoters hold in Rubicon Research Limited?
Promoters held 51.25% of Rubicon Research Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Rubicon Research Limited debt-free?
Its latest reported debt-to-equity ratio is 0.24.
What is Rubicon Research Limited's P/E ratio?
About 95.5, based on the last 12 months' earnings and a price of ₹1,657.4 (data 2026-11-02).
What is the 52-week high and low of Rubicon Research Limited?
The 52-week high is ₹1,899 and the 52-week low is ₹609.25.
Mutual funds holding Rubicon Research Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹268 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI MultiCap Fund | SBI Mutual Fund | 1.14% | ₹267 cr |
| Mirae Asset BSE Select IPO ETF | Mirae Asset Mutual Fund | 0.78% | ₹0 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.43% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Rubicon Research Limited | ₹1,657.4 | ₹26,650 cr | 95.5 | — | 27% | 32.4% | 0.24 | +169.8% |
| Anthem Biosciences Limited | ₹829.2 | ₹46,685 cr | 81.7 | — | 21.7% | 26% | 0.02 | +15.9% |
| Akums Drugs and Pharmaceuticals Limited | ₹730.3 | ₹11,520 cr | 38.3 | — | 8% | 9.8% | 0.05 | +55.7% |
| Fermenta Biotech Ltd | ₹420.45 | ₹1,229 cr | 20.3 | — | 18.7% | 20.8% | 0.28 | +35.6% |
| Fabtech Technologies Limited | ₹126.59 | ₹547 cr | 14.4 | 1.3 | 12.9% | 9.1% | 0.17 | -45.1% |
| Haleos Labs Ltd. | ₹1,420 | ₹411 cr | 27.2 | — | 8.4% | 10.4% | 0.52 | +22.0% |
Compare RUBICON with ANTHEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open RUBICON in TickerKhoj →